Geode Capital Management LLC Acquires 284,047 Shares of FibroBiologics, Inc. (NASDAQ:FBLG)

Geode Capital Management LLC grew its holdings in FibroBiologics, Inc. (NASDAQ:FBLG) by 90.0% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 599,760 shares of the company’s stock after buying an additional 284,047 shares during the quarter. Geode Capital Management LLC owned approximately 1.71% of FibroBiologics worth $1,854,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the business. Fund Evaluation Group LLC purchased a new stake in FibroBiologics in the second quarter worth $5,265,000. State Street Corp raised its holdings in FibroBiologics by 26.5% in the 3rd quarter. State Street Corp now owns 475,837 shares of the company’s stock worth $1,470,000 after purchasing an additional 99,789 shares in the last quarter. Bank of New York Mellon Corp bought a new position in FibroBiologics in the 2nd quarter worth $342,000. Mercer Global Advisors Inc. ADV bought a new stake in shares of FibroBiologics during the 2nd quarter valued at about $51,000. Finally, Rhumbline Advisers bought a new stake in shares of FibroBiologics during the 2nd quarter valued at about $115,000.

FibroBiologics Price Performance

Shares of FBLG stock opened at $2.06 on Thursday. FibroBiologics, Inc. has a one year low of $1.08 and a one year high of $55.00. The company’s 50-day moving average is $2.54 and its 200 day moving average is $3.02.

Analyst Ratings Changes

FBLG has been the subject of several research analyst reports. D. Boral Capital restated a “buy” rating and issued a $16.00 price objective on shares of FibroBiologics in a report on Friday, December 27th. Rodman & Renshaw started coverage on shares of FibroBiologics in a research note on Thursday, December 12th. They set a “buy” rating and a $12.00 price objective on the stock. Maxim Group assumed coverage on shares of FibroBiologics in a research note on Tuesday, September 24th. They set a “buy” rating and a $12.00 target price for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of FibroBiologics in a research report on Wednesday, November 13th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, FibroBiologics has an average rating of “Buy” and a consensus price target of $13.00.

FibroBiologics Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.